Abiraterone acetate is under clinical development by Tavanta Therapeutics and currently in Phase III for Metastatic Castration-Resistant Prostate Cancer (mCRPC). According to GlobalData, Phase III drugs for Metastatic Castration-Resistant Prostate Cancer (mCRPC) have a 42% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Abiraterone acetate’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Abiraterone acetate overview

Abiraterone acetate (DRGT-45) is under development for the treatment of metastatic castration-resistant prostate cancer and castrate-sensitive prostate cancer. It is administered orally. It acts by targeting CYP17. The drug candidate is developed based on Super-API technology.

Tavanta Therapeutics overview

Tavanta Therapeutics (Tavanta) is involved developing diverse pipeline of specialty drugs. It is headquartered in Media, Pennsylvania, the US.

For a complete picture of Abiraterone acetate’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.